Piper Jaffray Cuts Price Target on Nxstage Medical (NXTM) Following Mixed 4Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
February 10, 2016 8:04 AM ESTLAWRENCE, Mass., Feb. 10, 2016 /PRNewswire/ -- Â
Highlights:
Full-Year Revenue Increases to $336 million, up 11% from 2014 Full-Year Home Revenue Increases to $183 million, up 16% from 2014 Full-Year Operating Income from Products Business Increases to $9 million Company Highlights Significant Product Introductions for the Next Three Years For Third Consecutive Year, Company Targets 15% Annual Home Revenue GrowthNxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported record revenue for the fourth quarter and fiscal year ended... More
